scholarly journals Physicians’ Use of Patients’ Daily Reports of Quality of Life to Evaluate Treatment Response in Phase I Cancer Trials

2012 ◽  
Vol 03 (05) ◽  
pp. 582-588
Author(s):  
Felicity W. K. Harper ◽  
Elisabeth I. Heath ◽  
Marci E. J. Gleason ◽  
Louis Penner ◽  
Patricia LoRusso ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Phase I ◽  
Treatment Response ◽  
Cancer Trials

scholarly journals The TELE-DD project on treatment nonadherence in the population with type 2 diabetes and comorbid depression

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Juan Francisco Roy ◽  
María Luisa Lozano del Hoyo ◽  
Fernando Urcola-Pardo ◽  
Alicia Monreal-Bartolomé ◽  
Diana Cecilia Gracia Ruiz ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Type 2 Diabetes ◽  
Phase I ◽  
Clinical Depression ◽  
Point Prevalence ◽  
Diabetic Patients ◽  
Comorbid Depression ◽  
Shared Risk

AbstractDiabetic patients have increased depression rates, diminished quality of life, and higher death rates due to depression comorbidity or diabetes complications. Treatment adherence (TA) and the maintenance of an adequate and competent self-care are crucial factors to reach optimal glycaemic control and stable quality of life in these patients. In this report, we present the baseline population analyses in phase I of the TELE-DD project, a three-phased population-based study in 23 Health Centres from the Aragonian Health Service Sector II in Zaragoza, Spain. The objectives of the present report are: (1) to determine the point prevalence of T2D and clinical depression comorbidity and treatment nonadherence; (2) to test if HbA1c and LDL-C, as primary DM outcomes, are related to TA in this population; and (3) to test if these DM primary outcomes are associated with TA independently of shared risk factors for DM and depression, and patients’ health behaviours. A population of 7,271 patients with type-2 diabetes and comorbid clinical depression was investigated for inclusion. Individuals with confirmed diagnoses and drug treatment for both illnesses (n = 3340) were included in the current phase I. A point prevalence of 1.9% was found for the T2D-depression comorbidity. The prevalence of patients nonadherent to treatment for these diseases was 35.4%. Multivariate analyses confirmed that lower diabetes duration, increased yearly PCS visits, HbA1c and LDL-C levels were independently related to treatment nonadherence. These findings informed the development of a telephonic monitoring platform for treatment of nonadherence for people with diabetes and comorbid depression and further trial, cost-effectiveness, and prognostic studies (phases II and III).

scholarly journals Correction to: Planning and reporting of quality-of-life outcomes in cancer trials

2016 ◽  
Vol 27 (1) ◽  
pp. 209 ◽  
Author(s):  
S. Schandelmaier ◽  
K. Conen ◽  
E. von Elm ◽  
J.J. You ◽  
A. Blümle ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Life Outcomes ◽  
Quality Of Life Outcomes ◽  
Cancer Trials

scholarly journals Health-related quality of life as an endpoint in oncology phase I trials: a systematic review

BMC Cancer ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Frédéric Fiteni ◽  
Isabelle Le Ray ◽  
Ahmad Ousmen ◽  
Nicolas Isambert ◽  
Amélie Anota ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Systematic Review ◽  
Phase I ◽  
Phase I Trials ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related

scholarly journals Quality-of-Life Priorities in Patients with Thyroid Cancer: A Multinational European Organisation for Research and Treatment of Cancer Phase I Study

Thyroid ◽  
2016 ◽  
Vol 26 (11) ◽  
pp. 1605-1613 ◽  
Author(s):  
Susanne Singer ◽  
Olga Husson ◽  
Iwona M. Tomaszewska ◽  
Laura D. Locati ◽  
Naomi Kiyota ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Thyroid Cancer ◽  
Phase I ◽  
Phase I Study ◽  
European Organisation

scholarly journals Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years

2018 ◽  
Vol 36 (6) ◽  
pp. 563-571 ◽  
Author(s):  
Julie Lemieux ◽  
Michael D. Brundage ◽  
Wendy R. Parulekar ◽  
Paul E. Goss ◽  
James N. Ingle ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Aromatase Inhibitor ◽  
Short Form ◽  
Phase Iii ◽  
Secondary Outcome ◽  
Secondary Outcome Measure ◽  
Change Scores ◽  
Sf 36 ◽  
Cancer Trials

Purpose MA.17R was a Canadian Cancer Trials Group–led phase III randomized controlled trial comparing letrozole to placebo after 5 years of aromatase inhibitor as adjuvant therapy for hormone receptor–positive breast cancer. Quality of life (QOL) was a secondary outcome measure of the study, and here, we report the results of these analyses. Methods QOL was measured using the Short Form-36 (SF-36; two summary scores and eight domains) and menopause-specific QOL (MENQOL; four symptom domains) at baseline and every 12 months up to 60 months. QOL assessment was mandatory for Canadian Cancer Trials Group centers but optional for centers in other groups. Mean change scores from baseline were calculated. Results One thousand nine hundred eighteen women were randomly assigned, and 1,428 women completed the baseline QOL assessment. Compliance with QOL measures was > 85%. Baseline summary scores for the SF-36 physical component summary (47.5 for letrozole and 47.9 for placebo) and mental component summary (55.5 for letrozole and 54.8 for placebo) were close to the population norms of 50. No differences were seen between groups in mean change scores for the SF-36 physical and mental component summaries and the other eight QOL domains except for the role-physical subscale. No difference was found in any of the four domains of the MENQOL Conclusion No clinically significant differences were seen in overall QOL measured by the SF-36 summary measures and MENQOL between the letrozole and placebo groups. The data indicate that continuation of aromatase inhibitor therapy after 5 years of prior treatment in the trial population was not associated with a deterioration of overall QOL.

Sign in / Sign up

Export Citation Format

Share Document